TIDMOBD
RNS Number : 4918Z
Oxford BioDynamics PLC
16 May 2023
Oxford BioDynamics Plc
Notice of Interim Results and Investor Webinar
Oxford, UK - 16 May, 2023 - Oxford BioDynamics, Plc (AIM: OBD,
OBD" or the "Company" and, together with its subsidiaries, the
"Group"), a biotechnology company developing precision medicine
tests based on the EpiSwitch(R) 3D genomics platform, expects to
announce its interim results for the half-year ended 31 March 2023
on Tuesday 30 May 2023.
Following the release of the results, the Company's management
team will conduct a live presentation to investors via the
Yellowstone Advisory webinar platform. The online presentation is
open to both existing and potential shareholders. Questions may be
submitted both before and during the presentation by emailing
info@yellowstoneadvisory.com .
The webinar will take place at 2pm BST on 30 May 2023. To
register, please visit:
https://us02web.zoom.us/webinar/register/3216841534960/WN_XzaMPjm_TE6YFtNcxVxC1g
-Ends-
For further details please contact:
Oxford BioDynamics Plc
Jon Burrows, CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Adviser and Broker
Stephane Auton
John More +44 (0)20 7408 4090
-----------------------------------
Instinctif Partners
Melanie Toyne-Sewell +44 (0)20 7457 2020
Rozi Morris OxfordBioDynamics@instinctif.com
Adam Loudon
-----------------------------------
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
Its flagship product is EpiSwitch(R) CiRT (Checkpoint Inhibitor
Response Test) for cancer, a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in
February 2022.
OBD's next product will be the Prostate Screening EpiSwitch(R)
(PSE) blood test, due to be launched in Q4 2023.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch(R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit .
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial office in
Gaithersburg, MD, USA and a reference laboratory in Penang,
Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow OBD on Twitter
(@OxBioDynamics) and LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcomes, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFFFFLEDIELIV
(END) Dow Jones Newswires
May 16, 2023 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2023 to Apr 2024